Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005 - 2011

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Williamson, Deborah A ^a,b,c   Lim, Alwin ^a   Wiles, Siouxsie ^a   Roberts, Sally A ^b   Freeman, Joshua T ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Auckland District Health Board ^*  (New Zealand)

^c INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

Antimicrobial resistance; Bacteremia; Escherichia coli

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFALOTIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MEROPENEM; TIMENTIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIAN; BACTEREMIA; BLOOD CULTURE; BLOODSTREAM INFECTION; CHILD; COMMUNITY ASSOCIATED ESCHERICHIA COLI BLOODSTREAM INFECTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ESCHERICHIA COLI BACTEREMIA; ETHNIC GROUP; EUROPEAN; FEMALE; GENDER; GROUPS BY AGE; HEALTHCARE ASSOCIATED ESCHERICHIA COLI BLOODSTREAM INFECTION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MAORI; MORTALITY; NEW ZEALAND; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; BACTEREMIA; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DEMOGRAPHY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; NEW ZEALAND; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84882295418     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-385     Document Type: Article

References (36)

1. Russo TA, Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect 2003, 5(5):449-456. 10.1016/S1286-4579(03)00049-2, 12738001.
2. Hounsom L, Grayson K, Melzer M. Mortality and associated risk factors in consecutive patients admitted to a UK NHS trust with community acquired bacteremia. Postgrad Med J 2011, 87(1033):757-762. 10.1136/pgmj.2010.116616, 21798969.
3. Jackson LA, Benson P, Neuzil KM, Grandjean M, Marino JL. Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis 2005, 191(9):1523-1529. 10.1086/429344, 15809912.
4. Uslan DZ, Crane SJ, Steckelberg JM, Cockerill FR, St Sauver JL, Wilson WR, Baddour LM. Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Arch Intern Med 2007, 167(8):834-839. 10.1001/archinte.167.8.834, 17452548.
5. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 2008, 14(11):1041-1047. 10.1111/j.1469-0691.2008.02089.x, 19040476.
6. Laupland KB, Kibsey PC, Gregson DB, Galbraith JC. Population-based laboratory assessment of the burden of community-onset bloodstream infection in Victoria. Canada. Epidemiol Infect 2013, 141(1):174-180.
7. Gagliotti C, Balode A, Baquero F, Degener J, Grundmann H, Gur D, Jarlier V, Kahlmeter G, Monen J, Monnet DL, Rossolini GM, Suetens C, Weist K, Heuer O, EARS-Net Participants (Disease Specific Contact Points for AMR) Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 2011, 16(11):19819. EARS-Net Participants (Disease Specific Contact Points for AMR).
8. Schlackow I, Stoesser N, Walker AS, Crook DW, Peto TE, Wyllie DH, Infections in Oxfordshire Research Database Team Increasing incidence of Escherichia coli bacteremia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999-2011. J Antimicrob Chemother 2012, 67(6):1514-1524. 10.1093/jac/dks082, 22438437, Infections in Oxfordshire Research Database Team.
9. Melzer M, Welch C. Is Escherichia coli bacteremia preventable?. Lancet Infect Dis 2012, 12(2):103-104. 10.1016/S1473-3099(11)70356-5, 22281141.
10. Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, Pascale DG, Proli EM, Cauda R, Cicchetti A, Fadda G. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010, 54(10):4085-4091. 10.1128/AAC.00143-10, 2944559, 20660675.
11. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D'Inzeo T, Fadda G, Cauda R, Spanu T. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007, 51(6):1987-1994. 10.1128/AAC.01509-06, 1891412, 17387156.
12. Kennedy KJ, Roberts JL, Collignon PJ. Escherichia coli bacteremia in Canberra: incidence and clinical features. Med J Aust 2008, 188(4):209-213.
13. Tong SY, Van Hal SJ, Einsiedel L, Currie BJ, Turnidge JD. Impact of ethnicity and socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in indigenous Australians. BMC Infect Dis 2012, 12(1):249. 10.1186/1471-2334-12-249, 3548680, 23043704.
14. Flory JH, Joffe M, Fishman NO, Edelstein PH, Metlay JP. Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults. Epidemiol Infect 2009, 137(5):717-726. 10.1017/S0950268808001489, 2741180, 18925988.
15. Statistics New Zealand 2006 census of populations and dwellings. District Health Board Area summary tables (http://www.stats.govt.nz/Census/about-2006-census/district-health-board-area-summary-tables.aspx). Last accessed July 30th, 2013, Statistics New Zealand.
16. World Health Organization International statistical classification of diseases and related health problems 2010, 10, World Health Organization.
17. Williamson DA, Roberts SA, Ritchie SR, Coombs GW, Fraser JR, Heffernan H. Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus in New Zealand: rapid emergence of Sequence Type 5 (ST5)-SCCmec-IV as the dominant community-associated MRSA clone. PLoS One 2013, 8(4):E62020. 10.1371/journal.pone.0062020, 3636228, 23637953.
18. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; 22nd Informational Supplement M100-S22 2012, PA, USA: CLSI, Wayne, Clinical and Laboratory Standards Institute.
19. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18(3):268-281. 10.1111/j.1469-0691.2011.03570.x, 21793988.
20. Skogberg K, Lyytikainen O, Ollgren J, Nuorti JP, Ruutu P. Population-based burden of bloodstream infections in Finland. Clin Microbiol Infect 2012, 18(6):E170-6. 10.1111/j.1469-0691.2012.03845.x, 22512663.
21. Williamson DA, Ritchie SR, Lennon D, Roberts SA, Stewart J, Thomas MG, Baker MG. Increasing incidence and sociodemographic variation in community-onset Staphylococcus aureus skin and soft tissue infections in New Zealand children. Paed Infect Dis J 2013, 32(8):923-925.
22. Baker MG, Sneyd E, Wilson NA. Is the major increase in notified campylobacteriosis in New Zealand real?. Epidemiol Infect 2007, 135(1):163-170. 10.1017/S0950268806006583, 2870549, 16753076.
23. Arnold R, Galloway Y, McNicholas A, O'Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011, 29(40):7100-7106. 10.1016/j.vaccine.2011.06.120, 21803101.
24. Olesen B, Kolmos HJ, Orskov F, Orskov I, Gottschau A. Bacteremia due to Escherichia coli in a Danish university hospital, 1986-1990. Scand J Infect Dis 1995, 27(3):253-257. 10.3109/00365549509019018, 8539550.
25. Baker MG, Barnard LT, Kvalsvig A, Verrall A, Zhang J, Keall M, Wilson N, Wall T, Howden-Chapman P. Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study. Lancet 2012, 379(9821):1112-1119. 10.1016/S0140-6736(11)61780-7, 22353263.
26. Hill PC, Birch M, Chambers S, Drinkovic D, Ellis-Pegler RB, Everts R, Murdoch D, Pottumarthy S, Roberts SA, Swager C, Taylor SL, Thomas MG, Wong CG, Morris AJ. Prospective study of 424 cases of Staphylococcus aureus bacteremia: determination of factors affecting incidence and mortality. Intern Med J 2001, 31(2):97-103. 10.1111/j.1444-0903.2001.00029.x, 11480485.
27. Ritchie SR, Fraser JD, Libby E, Morris AJ, Rainey PB, Thomas MG. Demographic variation in community-based MRSA skin and soft tissue infection in Auckland. New Zealand. N Z Med J 2011, 124(1332):21-30.
28. Tukuitonga CR, Bell S, Robinson E. Hospial admission among Pacific children Auckland 1992-97. N Z Med J 2000, 113(1116):358-361.
29. Malcolm L. Inequities in access to and utilisation of primary medical care services for Maori and low income New Zealanders. N Z Med J 1996, 109(1030):356-358.
30. Smith J, Jackson G, Orr-Walker B, Jackson R, Sinclair S, Thornley S, Riddell T, Chan WC. A population-based approach to the estimation of diabetes prevalence and health resource utilisation. N Z Med J 2010, 123(1310):62-73.
31. Lenz R, Leal JR, Church DL, Gregson DB, Ross T, Laupland KB. The distinct category of healthcare associated bloodstream infections. BMC Infect Dis 2012, 12(85):2334.
32. Cheong HS, Kang CI, Kwon KT, Heo ST, Wi YM, Kim ES, Lee JS, Ko KS, Chung DR, Lee NY, Song JH, Peck KR. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteremia. J Antimicrob Chemother 2007, 60(6):1355-1360. 10.1093/jac/dkm378, 17923453.
33. Kang CI, Wi YM, Lee MY, Ko KS, Chung DR, Peck KR, Lee NY, Song JH. Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains. J Clin Microbiol 2012, 50(2):312-317. 10.1128/JCM.06002-11, 3264158, 22162561.
34. Williamson DA, Sidjabat HE, Freeman JT, Roberts SA, Silvey A, Woodhouse R, Mowat E, Dyet K, Paterson DL, Blackmore T, Burns A, Heffernan H. Identification and molecular characterisation of New Delhi metallo-beta-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. Int J Antimicrob Agents 2012, 39(6):529-533. 10.1016/j.ijantimicag.2012.02.017, 22526013.
35. Williamson DA, Heffernan H, Sidjabat H, Roberts SA, Paterson DL, Smith M, Freeman JT. Intercontinental transfer of OXA-181-producing Klebsiella pneumoniae into New Zealand. J Antimicrob Chemother 2011, 66(12):2888-2890. 10.1093/jac/dkr396, 21933789.
36. Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M, Freeman JT. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 2012, 54(10):1406-1412. 10.1093/cid/cis194, 22419681.